Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sosei, a Japan-based biopharmaceutical company, has reached an agreement to acquire 100% of Activus Pharma, a privately-held biopharmaceutical company based in Chiba, Japan.
Subscribe to our email newsletter
Activus’ core technologies in drug formulation using proprietary nano-particle processing is expected to form the basis of Sosei’s new platform technology.
Activus Pharma said that its Activus Pure Nano-particle Technology (APNT), unlike other nano-particle processing technologies, keeps compounds virtually free from contamination. At the same time, it can yield pharmaceutical ingredients with particle sizes ranging from 50 to 300nm levels.
Thus, APNT enables the development of injections, ophthalmic solutions and inhalations with poorly soluble compounds where high purity is required.
Both the entities claimed that the needs for nano-particle technology within the pharmaceutical industry are still largely unmet.
Sosei and Activus Pharma added that the technology can be expected to generate new development candidates for Sosei, and partnership with other pharmaceutical companies is expected to allow Sosei to realise revenue from this technology in a relatively short period of time.